TheProfitWatch

BBIO - BridgeBio Pharma, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
64.7 3.24 (5.01%) 0.0 (0.01%) 0.07 (0.1%) -1.09 (-1.58%) 0.0 (0.0%) 3.3 (5.11%) 0.0 (0.0%) 0.5 (0.78%)

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.95
Diluted EPS:
-0.95
Basic P/E:
-71.5158
Diluted P/E:
-71.5158
RSI(14) 1m:
60.39
VWAP:
67.96
RVol:

Events

Period Kind Movement Occurred At

Related News